The Wegovy prescribing information confirms that no clinically relevant drug-drug interactions were identified in pharmacology studies
In the SUSTAIN 6 CV outcomes trial (CVOT), once-weekly semaglutide (0.5 or 1.0 mg) added to standard of care significantly reduced the occurrence of a first major adverse CV event (MACE: CV death, nonfatal myocardial infarction [MI], or nonfatal stroke) vs placebo over 2 years in 3297 subjects with T2D and high CV risk [12]
For medications like semaglutide, a popular choice in diabetes and weight management treatments, having high-quality labels on each vial ensures that users and healthcare providers can easily read essential information
However, over-training without adequate recovery can deplete your stores
A biweekly schedule reduces the number of injections by half, which makes it simpler and more convenient for patients to manage semaglutide treatment with their busy lifestyles
Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared